With so many mature and emerging digital technologies, and no end of interesting use cases in Regulatory, how do we decide which ones are worth it? And most importantly, who pays vs who benefits?
This was the topic during our third LinkedIn live session with John Cogan.
For those who missed the live event, the session recording is available.
Enjoy!
What can you expect to see in the video?
- There are obviously a lot of digital technologies out there and so potentially a very large number of use cases, what are your thoughts on that specifically in regulatory?
- Economics of innovation. What does that mean?
- Can we look at some examples of who pays vs who benefits?
Visuals from the Session
About John Cogan
John is the Founder of JPC Advisory Limited, a company focused on consulting in Life Sciences R&D. Over the last 30+ years, John has held global leadership roles in Life Sciences Consulting, Innovation, Technology and R&D Operations.
Most recently, John led the Global R&D Advisory practice at Syneos Health Consulting. Previously John was the CTO for Kinapse and before that, the CTO at Genpact Regulatory Affairs. Prior to that, John had an extensive career in Industry, having worked for GSK, Shire, Daiichi-Sankyo and Mundipharma among others, where he held varied roles including leading regulatory operations, R&D IT internal consulting. IT shared services and outsourcing.
